163 related articles for article (PubMed ID: 37752406)
21. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
22. Inhibition MNK-eIF4E-β-catenin preferentially sensitizes gastric cancer to chemotherapy.
Yang X; Liu Z; Yin X; Zeng Y; Guo G
Fundam Clin Pharmacol; 2022 Aug; 36(4):712-720. PubMed ID: 35048413
[TBL] [Abstract][Full Text] [Related]
23. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
24. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
25. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.
Kentsis A; Topisirovic I; Culjkovic B; Shao L; Borden KL
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18105-10. PubMed ID: 15601771
[TBL] [Abstract][Full Text] [Related]
26. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
Liu Y; Zhao R; Fang S; Li Q; Jin Y; Liu B
Fundam Clin Pharmacol; 2021 Feb; 35(1):156-164. PubMed ID: 32446293
[TBL] [Abstract][Full Text] [Related]
27. Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death.
Othumpangat S; Kashon M; Joseph P
Mol Cell Biochem; 2005 Nov; 279(1-2):123-31. PubMed ID: 16283521
[TBL] [Abstract][Full Text] [Related]
28. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
29. p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer.
Bae HJ; Kang SK; Kwon WS; Jeong I; Park S; Kim TS; Kim KH; Kim H; Jeong HC; Chung HC; Rha SY
Biochem Pharmacol; 2021 Jan; 183():114320. PubMed ID: 33161023
[TBL] [Abstract][Full Text] [Related]
30. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
31. Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.
Wan J; Shi F; Xu Z; Zhao M
Int J Oncol; 2015 Dec; 47(6):2217-25. PubMed ID: 26498997
[TBL] [Abstract][Full Text] [Related]
32. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
33. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
Zhu Y; Wang C; Li M; Yang X
J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
35. Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.
Pettersson F; Del Rincon SV; Emond A; Huor B; Ngan E; Ng J; Dobocan MC; Siegel PM; Miller WH
Cancer Res; 2015 Mar; 75(6):1102-12. PubMed ID: 25608710
[TBL] [Abstract][Full Text] [Related]
36. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
37. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy.
Wang G; Li Z; Li Z; Huang Y; Mao X; Xu C; Cui S
Biomed Pharmacother; 2017 Dec; 96():750-756. PubMed ID: 29049978
[TBL] [Abstract][Full Text] [Related]
38. Eukaryotic initiating factor eIF4E is targeted by EBV-encoded miR-BART11-3p and regulates cell cycle and apoptosis in EBV-associated gastric carcinoma.
Wang H; Liu J; Zhang Y; Sun L; Zhao M; Luo B
Virus Genes; 2021 Aug; 57(4):358-368. PubMed ID: 34146250
[TBL] [Abstract][Full Text] [Related]
39. Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase.
Pandey K; Katuwal NB; Park N; Hur J; Cho YB; Kim SK; Lee SA; Kim I; Lee SR; Moon YW
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008374
[TBL] [Abstract][Full Text] [Related]
40. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]